{
  "id": 20931017,
  "title": "Alzheimer’s Breakthrough Targets Genes That May Raise Risk up to 12 Times",
  "url": "https://urgent.news/2026/11/20/alzheimers-breakthrough-targets-genes-that-may-raise-risk-up-to-12",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-20T18:16:12.000Z",
  "source": {
    "name": "Newsweek",
    "slug": "newsweek",
    "url": "https://www.newsweek.com/alzheimers-breakthrough-targets-genes-risk-12733222"
  },
  "original_language": "en",
  "account": "A groundbreaking gene therapy developed by scientists at the University of Bristol aims to target the APOE4 gene, a high-risk genetic factor for Alzheimer's disease. The therapy converts APOE4 into the lower-risk APOE3 gene, potentially reducing the risk of Alzheimer's by up to 12 times. The research, led by Dr. Kevin Kemp, began in 2024 and has shown promising results in converting APOE4 to APOE3 in human immune cells without causing harm to surrounding cells' DNA. The team is optimistic that this gene editing technique could eventually help in preventing or slowing down Alzheimer's in those at the highest risk. However, the therapy is still in the experimental stage, and several challenges, including ensuring the safety and efficiency of the gene-editing machinery in the human brain, must be overcome before it can become a viable treatment.",
  "summary": "Could an effective gene therapy for Alzheimer's be on the horizon? Dr. Kevin Kemp told Newsweek that he thinks so.",
  "key_points": [
    "University of Bristol scientists develop gene therapy targeting APOE4 gene.",
    "Therapy converts APOE4 to APOE3, reducing Alzheimer's risk up to 12 times.",
    "Research led by Dr. Kevin Kemp shows promising results in human immune cells."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}